Indicated for hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
CD molecules
CD34
D12592 Omidubicel (USAN) <US>
New drug approvals in the USA [br08319.html]
Cellular and gene therapy products
D12592
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D12592
